# A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar Pustulosis

> **NCT01845987** · PHASE2 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 49 (actual)

## Conditions studied

- Palmoplantaris Pustulosis

## Interventions

- **DRUG:** Placebo
- **DRUG:** CNTO 1959

## Key facts

- **NCT ID:** NCT01845987
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2015-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01845987

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01845987, "A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar Pustulosis". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01845987. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*